Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

ZJ Franklin; LM McShane; Finbarr O'Harte; Nigel Irwin

doi:10.1016/j.peptides.2014.08.002

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

ZJ Franklin
, LM McShane
, Finbarr O'Harte
, Nigel Irwin

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

Abstract

Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

Original language	English
Pages (from-to)	95-101
Journal	Peptides
Volume	60
DOIs	https://doi.org/10.1016/j.peptides.2014.08.002
Publication status	Published (in print/issue) - 18 Aug 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.peptides.2014.08.002

Cite this

@article{0987d86389954691b421ecbe10f55ef7,

title = "Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.",

abstract = "Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45\%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P",

author = "ZJ Franklin and LM McShane and Finbarr O'Harte and Nigel Irwin",

year = "2014",

month = aug,

day = "18",

doi = "10.1016/j.peptides.2014.08.002",

language = "English",

volume = "60",

pages = "95--101",

journal = "Peptides",

issn = "1873-5169",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

AU - Franklin, ZJ

AU - McShane, LM

AU - O'Harte, Finbarr

AU - Irwin, Nigel

PY - 2014/8/18

Y1 - 2014/8/18

N2 - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

AB - Modification to the structure of glucagon has provided a number of glucagon receptor antagonists with possible therapeutic application for diabetes. These novel peptide analogs include desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon. This study has evaluated the metabolic benefits of once daily administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon in high fat (45%) fed mice for 15 days. Administration of desHis1Pro4Glu9-glucagon and desHis1Pro4Glu9(Lys30PAL)-glucagon had no significant effect on body weight, food intake or circulating glucose concentrations during the treatment period. However, both peptides significantly (P

U2 - 10.1016/j.peptides.2014.08.002

DO - 10.1016/j.peptides.2014.08.002

M3 - Article

SN - 1873-5169

VL - 60

SP - 95

EP - 101

JO - Peptides

JF - Peptides

ER -

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this